ActiveSpans 3 functions & 2 industries
Updated ResMed Defies Sector Slump with Oura Deal, But Investors Remain Wary Amid ASX Health Woes
Healthcare is splitting between legacy margin pressure and digital models that can scale beyond the clinic.
What is this trend?
Wearables, cloud software and recurring-care partnerships are reshaping sleep medicine and rewarding companies that can grow without relying on one-off device sales.
- Sector weakness is exposing firms tied to cost inflation, debt and reimbursement pressure.
- Digital health partnerships are turning consumer data into clinical workflows and new revenue streams.
- Investors are favoring recurring, higher-margin models over hardware-only growth stories.
- Adoption still depends on payer support, competition and proof that new care paths improve outcomes.
What’s the latest?
ResMed’s aggressive digital push and supply chain overhaul are fueling growth and margin gains, positioning it to outpace industry headwinds and capitalize on new product launches.
How it developed earlier updates
ResMed is bucking the ASX healthcare slump—posting robust growth, inking a game-changing Oura deal, and eyeing a 39% upside—even as investors keep one hand on the panic button.
ResMed Defies Sector Slump with Oura Deal, But Investors Remain Wary Amid ASX Health Woes
Where this is playing out
Industries